# Safety and Efficacy of BAY 50-4798 in Patients With HIV Infection

> **NCT00059462** · PHASE1,PHASE2 · COMPLETED · sponsor: **Bayer** · enrollment: 56 (actual)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** Interleukin-2 SA
- **DRUG:** HAART

## Key facts

- **NCT ID:** NCT00059462
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-12
- **Primary completion:** 2005-03
- **Final completion:** 2005-03
- **Target enrollment:** 56 (ACTUAL)
- **Last updated:** 2014-12-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00059462

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00059462, "Safety and Efficacy of BAY 50-4798 in Patients With HIV Infection". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT00059462. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*